trending Market Intelligence /marketintelligence/en/news-insights/trending/AWIOzU-ivxmgjNapC-T0hg2 content esgSubNav
In This List

US FDA grants uniQure breakthrough therapy designation for hemophilia drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA grants uniQure breakthrough therapy designation for hemophilia drug

The U.S. FDA granted uniQure NV breakthrough therapy designation for AMT-060, an investigational gene therapy for patients with severe hemophilia B.

Hemophilia B is a serious and rare inherited disease in males characterized by insufficient blood clotting.

The designation is based on the ongoing phase 1 and 2 studies of the drug that show sustained increases in Factor IX, reductions in Factor IX replacement usage and a near cessation of spontaneous bleeding in patients with severe disease at up to 12 months follow-up.